Differently from classic SS, where a sarcomatous component is present; greater benefits are obtained if the treatment includes radiotherapy and adjuvant chemotherapy in addition to radical inguinal orchiectomy
Published success rates of inguinal orchiectomy
range from 20-75% (Level of evidence 4, Grade C).
 Ultrasonography: Large Scrotal exploration scrotal hematoma Inguinal orchiectomy
Computed tomography: Large right-sided hematocele of mixed attenuation consistent with acute hemorrhage and evidence of extravasation of contrast at the superior pole of the hematocele
yields satisfactory treatment results.
A patient in the older age group had inguinal orchiectomy
due to non-discrimination of scrotal mass, continuing clinical suspect of scrotal mass and high level of tumor possibility, after was determined to have paratesticular RMS.
The standard treatment for all testicular tumors in adults is radical inguinal orchiectomy
. In the setting of a pure teratoma with advanced disease and elevation of tumor markers, chemotherapy is the systemic therapy of choice .
A Lichtenstein surgical technique was performed with inguinal orchiectomy
. The pathologist indicated the presence of saccular proliferation in the wall of the hernia with cysts and simple epithelium without stromal invasion (Figure 1(a)).
He was two months status post radical inguinal orchiectomy
for right testicular mature teratoma with retroperitoneal and mediastinal nodal metastases, with no follow up after surgery because of a lack of health insurance.
Radical inguinal orchiectomy
followed by retroperitoneal lymph node dissection is recommended for all children over the age of 10 and for those younger than 10 years old with the retroperitoneal disease.
As per Coleman et al, the accepted treatment for para-testicular sarcoma is radical inguinal orchiectomy
. Patients with an initial incomplete resection should undergo repeat wide excision.
Left inguinal orchiectomy
was performed under regional anesthesia.
A radical inguinal orchiectomy
is the procedure of choice in treating a malignant testicular mass (NCI, 2008b).